Director at Halozyme (NASDAQ: HALO) sells shares under Rule 10b5-1 plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported an open-market sale of common stock. On June 1, 2026, she sold 1,625 shares at an average price of $66.21 per share. After this transaction, she holds 43,669 shares of Halozyme common stock directly.

The footnotes state that these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 29, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 1,625 shares ($107,591)

Net Sell 1 txn

Insider Connaughton Bernadette

Role null

Sold 1,625 shs ($108K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,625	$66.21	$108K

Holdings After Transaction: Common Stock — 43,669 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 1,625 shares Sale price per share: $66.21 per share Shares held after transaction: 43,669 shares +1 more

4 metrics

Shares sold 1,625 shares Open-market sale of Halozyme common stock on June 1, 2026

Sale price per share $66.21 per share Average price for the 1,625 shares sold

Shares held after transaction 43,669 shares Director’s direct Halozyme holdings following the sale

10b5-1 plan adoption date May 29, 2025 Date the written trading plan governing these sales was adopted

Key Terms

Form 4, Rule 10b5-1, written trading plan, open-market sale, +1 more

5 terms

Form 4 regulatory

"The sales reported on this Form 4 were made pursuant to a written trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Rule 10b5-1 regulatory

"adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

written trading plan financial

"The sales reported on this Form 4 were made pursuant to a written trading plan"

open-market sale financial

"transaction_action is described as an open-market sale of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

non-derivative financial

"The transaction type is classified as non-derivative common stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 05:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Connaughton Bernadette

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		S⁽¹⁾		1,625	D	$66.21	43,669	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Halozyme (HALO) report on this Form 4?

Halozyme reported that director Bernadette Connaughton sold 1,625 shares of common stock in an open-market transaction at an average price of $66.21 per share, leaving her with 43,669 shares held directly after the sale.

Who is the insider involved in the latest Halozyme (HALO) Form 4 filing?

The insider is Bernadette Connaughton, a director of Halozyme Therapeutics, Inc. She reported an open-market sale of 1,625 shares of common stock and now directly owns 43,669 Halozyme shares following the reported transaction.

How many Halozyme (HALO) shares did the director sell and at what price?

Director Bernadette Connaughton sold 1,625 Halozyme common shares at an average price of $66.21 per share. The transaction was categorized as an open-market sale of non-derivative common stock according to the Form 4 data.

How many Halozyme (HALO) shares does the director hold after this Form 4 trade?

After the reported sale, director Bernadette Connaughton holds 43,669 shares of Halozyme common stock directly. This post-transaction holding is disclosed in the Form 4 under the total shares following the transaction field.

Was the Halozyme (HALO) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the sales were made under a written trading plan adopted on May 29, 2025, in accordance with Rule 10b5-1, indicating the trades were pre-arranged rather than opportunistic.

What type of transaction code is shown in the Halozyme (HALO) Form 4?

The Form 4 lists transaction code "S," which represents a sale in an open-market or private transaction. In this case, it reflects the open-market sale of 1,625 shares of Halozyme common stock by director Bernadette Connaughton.